TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/04/2026
Back to search
Official data from USPTO
TEVA CLOZAPINE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
42
Latest update
02/05/2026
Trademark type
Combined
Nice classes
5
Filing date
03/26/2010
Registration date
05/17/2011
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/17/2021
Last transaction
02/05/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
03/17/2010
First use in commerce
03/17/2010
Drawing code
3
Owner type
03
Owner location
Parsippany, NJ
Examiner
SAPPENFIELD, ANN
Law office
M80
Current location
GENERIC WEB UPDATE
Mark description
The mark consists of the stylized words "TEVA CLOZAPINE" with a three part design in between the words "TEVA" and "CLOZAPINE".
Holders and representatives
Holders
Teva Pharmaceuticals USA, Inc.
Teva Pharmaceuticals USA, Inc.
Representatives
Lori Wolfe Teva Pharmaceuticals USA, Inc.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
a full line of prescription pharmaceuticals featuring the ingredient clozapine
Publications
History of USPTO decisions and trademark events.
42 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/04/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/04/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/04/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/04/2026
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
09/17/2021
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
09/17/2021
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
09/17/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/17/2021
E89R
TEAS SECTION 8 & 9 RECEIVED
05/17/2021
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
05/17/2020
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
10/31/2017
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
10/31/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/31/2017
E815
TEAS SECTION 8 & 15 RECEIVED
10/09/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/09/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
05/17/2011
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/01/2011
PUBO
PUBLISHED FOR OPPOSITION
03/01/2011
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
01/27/2011
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/24/2011
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/20/2011
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/20/2011
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/20/2011
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/18/2011
GNRT
NON-FINAL ACTION E-MAILED
01/18/2011
CNRT
NON-FINAL ACTION WRITTEN
01/18/2011
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
01/05/2011
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
01/03/2011
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
12/21/2010
ALIE
ASSIGNED TO LIE
12/21/2010
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/30/2010
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/24/2010
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/24/2010
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/24/2010
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/18/2010
GNRT
NON-FINAL ACTION E-MAILED
06/18/2010
CNRT
NON-FINAL ACTION WRITTEN
06/18/2010
DOCK
ASSIGNED TO EXAMINER
06/07/2010
MDSC
NOTICE OF DESIGN SEARCH CODE MAILED
04/01/2010
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/31/2010
NWAP
NEW APPLICATION ENTERED
03/30/2010
Continuous trademark protection
Get notified about every new filing that threatens TEVA CLOZAPINE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.